Daunorubicin and doxorubicin (DOX) (Fig. 1) are members of the family of the anthracycline antibiotics (1, 2) that were introduced into cancer therapy about 3 decades ago. As a result of a small structural difference, DOX is a much more potent anticancer agent than daunorubicin. Since its introduction into human cancer therapy, DOX is still the most widely used chemotherapeutic drug, with the broadest spectrum of antitumor effect (3) .
The antiproliferative activity of DOX is due mainly to its ability to intercalate into DNA and break the strands of double helix by inhibiting topoisomerase 11 (4) . Despite its wide acceptance in the chemotherapy of various cancers, prolonged use of DOX is severely limited by cardiotoxicity (5) . Another limitation of DOX is multidrug resistance (6) .
Thousands of anthracycline derivatives were synthesized to overcome these limitations and in search for even more active analogs (3) . One of the most significant milestones in the semisynthetic development of more potent, non-crossresistant analogs of DOX with lower cardiotoxicity was the finding of 3-cyanomorpholinodoxorubicin (MRA-CN) (7, The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 8 ). This derivative was isolated as a highly potent by-product that formed during the reductive alkylation of the daunosamine nitrogen of DOX. MRA-CN was 100-500 times more active than DOX in vitro. In fact, MRA-CN proved to be 1500 times more potent on cell lines resistant to DOX (9) (10) (11) . It was revealed that the extremely high activity of this compound, even against DOX-resistant tumor cell lines, is a result of its ability to form an aminal adduct with an amino group of a guanine base in close vicinity to its binding site (12, 13) . Based on this knowledge, a class of intensely potent analogs was developed, best represented by N-(5,5-diacetoxypent-1-yl)doxorubicin (14, 15) . This analog is a water soluble, latent aldehyde derivative, activated in tissues by carboxylate esterase enzymes to become 150 times more active than DOX. Other semisynthetic derivatives, like morpholinodoxorubicin (7) and 2-methoxymorpholinodoxorubicin, become 50-80 times more active in vivo after activation by liver enzymes (16, 17) .
These highly potent analogs of DOX either have a latent aldehyde derivative attached to the nitrogen atom in the daunosamine moiety through an open chain polymethylene bridge or the nitrogen atom becomes a part of a morpholine ring. Gao et al. (18) presented a high resolution x-ray diffraction picture of a covalently linked adduct between a synthetic DNA segment and a daunorubicin derivative. This adduct forms readily when traces of formaldehyde are present in the crystallization solvent. The daunosamine nitrogen atom of the anthracycline derivative was shown to be linked covalently through a methylene bridge to the amino group of an aminoadenine moiety of the DNA segment in close vicinity.
Based on these findings, we decided to investigate further the structural requirements for the design of intensely potent doxorubicin analogs. Our efforts led to the high yield (85%) conversion of DOX to 2-pyrrolinodoxorubicin by the use of a 30-fold excess of 4-iodobutyraldehyde. 2-Pyrrolinodoxorubicin is a stable, water soluble analog, which is 500-1000 times more active than its parent compound in vitro.
MATERIALS AND METHODS
Materials. DOX HCl salt, 1,4-diiodobutane, a,a'-dichloroortho-xylene, cis-1,4-dichloro-2-butene, 3-bromopropionyl chloride, and 4-bromobutyryl chloride were purchased from Aldrich. Silica gel (Merck grade 9385; 230-400 mesh; pore size, 60 A) was also from Aldrich. TLC aluminum sheets Proc. Natl. Acad. Sci. USA 93 (1996) Preparation of 4-iodobutyraldehyde, 5-iodovaleraldehyde, and 5-iodo-2-petanone. 2-(3-Chloropropyl)-1,3-dioxolane, (1.3 ml; 10 mmol) was dissolved in 200 ml of acetone containing 30 g (200 mmol; 20-fold excess) of Nal. The solution was refluxed for 24 hr followed by evaporation to dryness. Diethyl ether (100 ml) was used to extract the organic material from the inorganic solid residue. The ethereal solution was then washed with 50 ml of H20/50 ml of 5% (wt/vol) aqueous Na2S203 solution and then three times again with 50 ml of H20. The ether was removed in vacuo and the remaining oil was dissolved in 3 ml of 50% (vol/vol) aqueous AcOH. After 1 hr, 100 ml of ether was added to this solution and the acetic acid as well as the ethylene glycol were removed by washing three times with 50 ml of H20. The main product eluted with Rf = 0.8 on TLC in CHCl3. The spot test used for characterizing the aldehyde function was the same as cited above (19) . The ether was then removed and the black oily residue was applied on a column packed with silica gel as described. Purification resulted in 1.6 g of yellow oil (yield, 80%.) 5-lodovaleraldehyde and 5-iodo-2-pentanone were obtained exactly the same way starting from 2-(4-chlorobutyl)-1,3-dioxolane or 2-(3-chloropropyl)-2-methyl-1,3-dioxolane, respectively.
Preparation of 3'-deamino-3'-(pyrrolidine-1"-yl)doxorubicin trifluoroacetic acid (TFA) salt (AN-181). DOX HCl salt (50 mg; 86 ,umol) was dissolved in 1 ml of dimethylformamide (DMF) and 171 ,lI (1.3 mmol; 15-fold excess) of 1,4-diiodobutane was added, followed by 45 ul (260 ,umol; 3-fold excess) of N,N-diisopropylethylamine (DIPEA). After 16 hr, the reaction is complete as assessed by analytical HPLC. The solvent was evaporated in vacuo and the residual oil was dissolved in 3 ml of 0.1% TFA in H20 and extracted with ether to remove excess 1,4-diiodobutane. Purification by HPLC resulted in 41.6 mg of 98% pure DOX derivative (yield, 68%).
Preparation of 3'-deamino-3'-(isoindoline-2"-yl)doxorubicin TFA salt (AN-184). DOX HCl salt (50 mg; 86 ,umol) was dissolved in 1 ml of DMF and 226 mg (1.3 mmol; 15-fold excess) of a,a'-dichloro-ortho-xylene was added followed by 45 ,tl (260 ,tmol; 3-fold excess) of DIPEA and a catalytic amount of Nal. After 16 hr, the reaction was complete and the desired end product was isolated as given above (yield, 55%).
Preparation of 3'-deamino-3'-(3"-pyrroline-1"-yl)doxorubicin TFA salt (AN-185). DOX HCl salt (50 mg; 86 ,umol) was dissolved in 1 ml of DMF and 136.8 gl (1.3 mmol; 15-fold excess) of cis-1,4-dichloro-2-butene was added, followed by 45 ,ul (260 ,tmol; 3-fold excess) of DIPEA. After 16 hr, the reaction mixture was worked up as described above, yielding 22.6 mg of 98% pure end product (yield, 37%).
Preparation of 3'-deamino-3'-(3"-pyrrolidone-1"-yl)doxorubicin TFA salt (AN-191) and 3'-deamino-3'-(3"-piperidone-1"-yl)doxorubicin TFA salt . DOX HCl salt (50 mg; 86 ,umol) was dissolved in 1 ml of DMF and 241 mg (1.3 mmol; 15-fold excess) of 1-chloro-4-bromo-2-butanone was added followed by 45 ,ul (260 ,umol; 3-fold excess) of DIPEA. After 16 hr, the reaction mixture was purified as cited above, yielding 20.6 mg of 98% pure end product (yield, 33%). 3'-Deamino-3'-(3"-piperidone-1"-yl)doxorubicin was prepared similarly by using 1-chloro-5-bromo-2-pentanone (yield, 28%). 100 ,lI of glacial acetic acid was added to the reaction mixture, which was then added dropwise to 5 ml of 0.1% TFA in 70% aqueous acetonitrile. This solution was diluted with 2 ml of 0.1% aqueous TFA solution, followed by removal of the acetonitrile in vacuo. The resulting aqueous solution was extracted with hexane to remove the excess of the halogen compound. After purification by HPLC, 52 mg of 98% pure end product was obtained (yield, 85%). 3'-Deamino-3'-(1",3"-tetrahydropyridine-1"-yl)doxorubicin TFA salt (AN-205) and 3'-deamino-3'-(2"-methyl-2"-pyrroline-1"-yl)doxorubicin TFA salt (AN-204) were prepared similarly from 5-iodovaleraldehyde (yield, 75%) and 5-iodo-2-pentanone (yield, 54%), respectively.
Purification. The final purification of all the crude products was carried out on a Beckman model 342 semipreparative HPLC system, using an Aquapore Octyl (250 x 10 mm; pore size, 300 A; particle size, 15 spectrometer Finnigan-MAT TSQ 7000 were used for structural identification of the DOX derivatives (Fig. 2) . RESULTS A convenient synthetic procedure was developed for conversion of DOX to 2-pyrrolino-DOX. This derivative, which has the daunosamine nitrogen of DOX incorporated in a five-membered ring, is 500-1000 times more potent than DOX (Tables 1-3) . A conversion of >90% of DOX (Fig. 3) was achieved by using a 30-fold excess of 4-iodobutyraldehyde in anhydrous DMF in the presence of a tertiary base. The reaction is complete within 15 min and, after purification by HPLC, the yield is >85%. 4-lodobutyraldehyde was obtained from the commercially available 2-(3-chloropropyl)-1,3-dioxolane by refluxing it in acetone containing a 20-fold excess of Nal. After hydrolysis of the acetal, flash chromatography was used to isolate an oil with 80% yield. 5-Iodovaleraldehyde was similarly prepared from 2-(4-chlorobutyl)-1,3-dioxolane. This reagent was used for conversion of doxorubicin to 1,3-tetrahydropyridino-DOX, a homolog of 2-pyrrolino-DOX, incorporating the daunosamine nitrogen in a six-membered ring. Interestingly, 2-pyrrolino-DOX showed antiproliferative activity in vitro 30-50 times higher than its homolog with a six-membered ring, as shown in Tables 1-3 . A similar phenomenon was observed when the in vitro cytotoxic activities of 3-pyrrolidono-DOX (containing a five-membered ring) and 3-piperidono-DOX (with a six-membered ring) were compared, the former being -5 times more active than the latter. 3-Pyrrolidono-DOX was also 10 times more active than DOX ( Table 3 ). While the chemistry of 2-pyrrolidone or 2-piperidone derivatives of primary amines was studied very extensively, the literature on the preparation of 3-pyrrolidone and 3-piperidone derivatives is rather limited. The syntheses previously described for preparation of such analogs involved extreme conditions (21) not applicable for derivatization of the complex, chemically sensitive structure of DOX. The conversion of DOX to these derivatives was achieved again by alkylation with reactive halogen compounds. A 15-fold excess of 1-chloro-4-bromo-2-butanone was reacted with DOX in anhydrous DMF in the presence of a 3-fold excess of a tertiary base, leading to the formation of 3-pyrrolidono-DOX with a moderate yield of 33%. Its homolog counterpart, bearing a six-membered 3-piperidone ring at the 3' position of the daunosamine moiety, was prepared under similar conditions by using 1-chloro-5-bromo-2-pentanone. The yield was 28%. For preparation of 1-chloro-4-bromo-2-butanone, 3-bromopropionyl chloride was reacted with excess diazomethane in ether and the resulting diazomethyl ketone was converted to the corresponding chloromethyl ketone by anhydrous HCl in ether. Flash chromatography of the halogen derivative thus obtained lead to a clear oil in a yield of 80%. 1-Chloro-5-bromo-2-pentanone was prepared similarly from 4-bromobutyryl chloride. Cells were incubated in RPMI 1640 medium containing 6 mM L-glutamine and 10% fetal bovine serum in 96-well plates. Relative cell number in treated and control plates was determined by crystal violet staining and is expressed as T/C values as defined in Table 1 .
To further elucidate structural requirements for the design of intensely potent daunosamine-modified DOX analogs, 2-methyl-2-pyrrolino-DOX and 3-pyrrolino-DOX, a structural isomer of 2-pyrrolino-DOX, were also synthesized. 2-Methyl-2-pyrrolino-DOX has a methyl substituent on the reactive carbon atom 2 of the ring and, surprisingly, it was even less active than DOX. The synthesis was done similarly to that of 2-pyrrolino-DOX, but using 5-iodo-2-pentanone for alkylation. In the structure of 3-pyrrolino-DOX, the double bond is between carbon atoms 3 and 4 of the five-membered ring. This analog was -5 times more active than DOX in inhibiting growth of the MCF-7 human breast cancer cell line in vitro. Synthesis was accomplished by reacting a 15-fold excess of cis-1,4-dichloro-2-butene (22) with DOX in the presence of an excess of tertiary base. The yield was 37% after purification by HPLC.
Pyrrolidino-DOX was synthesized by using the alkylating agent 1,4-diiodobutane. The yield was 70%. The fivemembered ring, attached to the 3' position of the daunosamine moiety of DOX in this analog, had no reactive double bond or oxo function in its structure. The activity of pyrrolidino-DOX was only slightly better than that of DOX in vitro.
A more lipophilic DOX analog, isoindolino-DOX, was also prepared in a satisfactory yield (55%) by using an excess of a,a'-dichloro-ortho-xylene. This analog was more potent than DOX at higher concentrations but less active at lower concentrations. the daunosamine nitrogen, in the form of open-chain Nalkanal derivatives (7, 15, 23) .
To investigate further the structural requirements of intensely potent DOX derivatives, analogs with five-and six-membered rings at the 3' position of the daunosamine moiety were designed and synthesized. Interestingly, analogs that incorporated the daunosamine nitrogen in a fivemembered ring, having a reactive "alkylating" function, were markedly more active in vitro than their counterparts with a six-membered ring ( Table 3 ). The reactive function was either a double bond or an oxo group. 2-Pyrrolino-DOX has a double bond between carbon atoms 2" and 3" of its five-membered ring. Its homolog, 1,3-tetrahydropyridino-DOX, also has a double bond between carbon atoms 2" and 3" of its six-membered ring. Both analogs are enamines-that is, latent aldehydes-but the former was 30-50 times more active than the latter, as shown in Table 3 . An explanation for this great difference in activities may be found in a steric distinction between the five-and the six-membered rings. It is well known that five-membered rings are almost planar while six-membered rings take the three-dimensional shape of a "chair" or a "tub." As is shown in Fig. 4 In addition, our results demonstrate that analogs having the daunosamine nitrogen incorporated in a ring that has a reactive carbon atom vicinal to the nitrogen are markedly more active than those having a CH2 group between these two atoms. Thus, 2-pyrrolino-DOX is -100 times more active than 3-pyrrolino-DOX.
The high yield, clear-cut conversion of DOX to 2-pyrrolino-DOX was facilitated by use of 4-iodobutyraldehyde. An excessive amount of the aldehyde derivative has to be reacted first with a salt of the amino alcohol in an anhydrous polar solvent like DMF. This is followed by addition of a tertiary base. When the base was added to the reaction mixture prior to addition of the aldehyde, the formation of several byproducts was observed. The reaction with the aldehyde leads to formation of a five-membered oxazolidine ring having a iodopropyl side chain at its carbon atom 2. In this ring, the daunosamine nitrogen is a secondary amine. Basification of the reaction mixture leads quickly to construction of a fused ring system by alkylation of the secondary nitrogen with the reactive iodopropyl side chain. The quick formation of a thermodynamically favorable five-membered ring protects the secondary nitrogen from derivatization by excess of the reactive halogen compound present. Acidification of the reaction mixture with dilute aqueous acid leads to formation of 2-pyrrolino-DOX, a stable, water soluble derivative that is 500-1000 times more potent than DOX. Analogous reactions take place between 5-iodovaleraldehyde or 5-iodo-2-pentanone and vicinal amino alcohols. The corresponding morpholino derivative may be prepared by using 2-(2-iodoethoxy)acetaldehyde.
The utilization of this reaction for formation of targeted cytotoxic luteinizing hormone-releasing hormone analogs (24) with lower peripheral toxicity has been accomplished, and the chemistry of the conjugation and the in vivo activity of the resulting hybrids, intended for cancer therapy, will be the subject of subsequent publications.
